The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs.
cryosynthesis
cryotemperature
nanoparticles
polymorphism
poorly soluble drug
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Jan 2020
01 Jan 2020
Historique:
received:
07
11
2019
revised:
12
12
2019
accepted:
25
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Among the significant problems of modern pharmacology are the low solubility and bioavailability of drugs. One way to resolve this problem is to obtain new polymorphic forms of drugs with improved physicochemical properties. Various approaches have been developed with this aim, including the preparation of co-crystals, the use of nanoparticles, or the use of compounds in the form of a salt. A promising direction in pharmacology concerns the production of new stable polymorphic structures. In this mini-review, we consider certain aspects of drug polymorphism, methods for the synthesis of polymorphs, and the stability, size, and transformation of crystalline polymorphs. Moreover, we summarize our results from several studies demonstrating the problems associated with the synthesis of new polymorphous modifications based on inert gases and cryotemperatures. The results indicate that the problems specific to drug polymorphisms have only been partly resolved, are of current interest, and require further development.
Identifiants
pubmed: 31906357
pii: pharmaceutics12010034
doi: 10.3390/pharmaceutics12010034
pmc: PMC7022426
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Adv Drug Deliv Rev. 2017 Aug 1;117:71-85
pubmed: 27940141
Int J Pharm. 2013 Aug 30;453(1):142-56
pubmed: 23000841
Pharm Dev Technol. 2014 Nov;19(7):779-88
pubmed: 24032356
J Pharm Sci. 2006 Aug;95(8):1641-65
pubmed: 16802362
Expert Opin Drug Deliv. 2015;12(11):1741-54
pubmed: 26098043
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2180-4
pubmed: 12604798
Acta Crystallogr Sect E Struct Rep Online. 2010 Sep 25;66(Pt 10):o2623
pubmed: 21587597
Eur J Pharm Sci. 2019 Sep 1;137:104967
pubmed: 31252052
Chem Soc Rev. 2015 Dec 7;44(23):8619-35
pubmed: 26400501
Pharm Res. 1995 Jul;12(7):945-54
pubmed: 7494814
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3145-53
pubmed: 17048530
Pharm Nanotechnol. 2018;6(3):147-164
pubmed: 29984674
Adv Drug Deliv Rev. 2016 May 1;100:85-101
pubmed: 26826438
Pharm Dev Technol. 2005;10(2):291-7
pubmed: 15926678
Int J Pharm. 2009 May 21;373(1-2):124-32
pubmed: 19429297
Curr Pharm Des. 2018;24(21):2375-2382
pubmed: 29766778
Curr Drug Discov Technol. 2017;14(2):72-105
pubmed: 27908255
Mini Rev Med Chem. 2014;14(10):853-61
pubmed: 25307305
Pharmaceutics. 2018 Jul 31;10(3):
pubmed: 30065221
Molecules. 2017 Aug 21;22(8):
pubmed: 28825659
ISRN Pharm. 2012;2012:195727
pubmed: 22830056
Pharmaceutics. 2018 Aug 21;10(3):
pubmed: 30134537
Curr Med Chem. 2009;16(7):884-905
pubmed: 19275600
Faraday Discuss. 2018 Oct 26;211(0):441-458
pubmed: 30047976
Eur J Pharm Sci. 2013 Jan 23;48(1-2):142-52
pubmed: 23085547
Pharm Res. 2001 Jun;18(6):859-66
pubmed: 11474792
Int J Pharm. 2013 Aug 30;453(1):126-41
pubmed: 23333709
Adv Drug Deliv Rev. 2016 May 1;100:116-25
pubmed: 26805787
Molecules. 2015 Oct 15;20(10):18759-76
pubmed: 26501244
Int J Pharm. 2013 Nov 30;457(1):187-96
pubmed: 24076396
Eur J Pharm Sci. 2010 Jul 11;40(4):325-34
pubmed: 20417274
J Pharm Bioallied Sci. 2010 Jan;2(1):2-7
pubmed: 21814422
AAPS PharmSciTech. 2010 Sep;11(3):1493-8
pubmed: 20857350
Int J Pharm. 2011 Apr 15;408(1-2):138-51
pubmed: 21272627
J Pharm Sci. 2007 Dec;96(12):3419-31
pubmed: 17621678